Base de dados : MEDLINE
Pesquisa : C18.452.584.500.500 [Categoria DeCS]
Referências encontradas : 24372 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 2438 ir para página                         

  1 / 24372 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Registro de Ensaios Clínicos
Texto completo
[PMID]:29340676
[Au] Autor:Salminen P; Helmiö M; Ovaska J; Juuti A; Leivonen M; Peromaa-Haavisto P; Hurme S; Soinio M; Nuutila P; Victorzon M
[Ad] Endereço:Division of Digestive Surgery and Urology, Turku University Hospital, Turku, Finland.
[Ti] Título:Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial.
[So] Source:JAMA;319(3):241-254, 2018 01 16.
[Is] ISSN:1538-3598
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Importance: Laparoscopic sleeve gastrectomy for treatment of morbid obesity has increased substantially despite the lack of long-term results compared with laparoscopic Roux-en-Y gastric bypass. Objective: To determine whether laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass are equivalent for weight loss at 5 years in patients with morbid obesity. Design, Setting, and Participants: The Sleeve vs Bypass (SLEEVEPASS) multicenter, multisurgeon, open-label, randomized clinical equivalence trial was conducted from March 2008 until June 2010 in Finland. The trial enrolled 240 morbidly obese patients aged 18 to 60 years, who were randomly assigned to sleeve gastrectomy or gastric bypass with a 5-year follow-up period (last follow-up, October 14, 2015). Interventions: Laparoscopic sleeve gastrectomy (n = 121) or laparoscopic Roux-en-Y gastric bypass (n = 119). Main Outcomes and Measures: The primary end point was weight loss evaluated by percentage excess weight loss. Prespecified equivalence margins for the clinical significance of weight loss differences between gastric bypass and sleeve gastrectomy were -9% to +9% excess weight loss. Secondary end points included resolution of comorbidities, improvement of quality of life (QOL), all adverse events (overall morbidity), and mortality. Results: Among 240 patients randomized (mean age, 48 [SD, 9] years; mean baseline body mass index, 45.9, [SD, 6.0]; 69.6% women), 80.4% completed the 5-year follow-up. At baseline, 42.1% had type 2 diabetes, 34.6% dyslipidemia, and 70.8% hypertension. The estimated mean percentage excess weight loss at 5 years was 49% (95% CI, 45%-52%) after sleeve gastrectomy and 57% (95% CI, 53%-61%) after gastric bypass (difference, 8.2 percentage units [95% CI, 3.2%-13.2%], higher in the gastric bypass group) and did not meet criteria for equivalence. Complete or partial remission of type 2 diabetes was seen in 37% (n = 15/41) after sleeve gastrectomy and in 45% (n = 18/40) after gastric bypass (P > .99). Medication for dyslipidemia was discontinued in 47% (n = 14/30) after sleeve gastrectomy and 60% (n = 24/40) after gastric bypass (P = .15) and for hypertension in 29% (n = 20/68) and 51% (n = 37/73) (P = .02), respectively. There was no statistically significant difference in QOL between groups (P = .85) and no treatment-related mortality. At 5 years the overall morbidity rate was 19% (n = 23) for sleeve gastrectomy and 26% (n = 31) for gastric bypass (P = .19). Conclusions and Relevance: Among patients with morbid obesity, use of laparoscopic sleeve gastrectomy compared with use of laparoscopic Roux-en-Y gastric bypass did not meet criteria for equivalence in terms of percentage excess weight loss at 5 years. Although gastric bypass compared with sleeve gastrectomy was associated with greater percentage excess weight loss at 5 years, the difference was not statistically significant, based on the prespecified equivalence margins. Trial Registration: clinicaltrials.gov Identifier: NCT00793143.
[Mh] Termos MeSH primário: Gastrectomia
Derivação Gástrica
Laparoscopia
Obesidade Mórbida/cirurgia
Perda de Peso
[Mh] Termos MeSH secundário: Adolescente
Adulto
Diabetes Mellitus Tipo 2/complicações
Feminino
Seguimentos
Gastrectomia/efeitos adversos
Gastrectomia/métodos
Derivação Gástrica/efeitos adversos
Derivação Gástrica/métodos
Seres Humanos
Hiperlipidemias/complicações
Hipertensão/complicações
Masculino
Meia-Idade
Obesidade Mórbida/complicações
Obesidade Mórbida/fisiopatologia
Complicações Pós-Operatórias
Qualidade de Vida
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; EQUIVALENCE TRIAL; JOURNAL ARTICLE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180311
[Lr] Data última revisão:
180311
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180118
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1001/jama.2017.20313


  2 / 24372 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:29267671
[Au] Autor:Lutfioglu M; Aydogdu A; Atabay VE; Sakallioglu EE; Avci B
[Ad] Endereço:Ondokuz Mayis University Faculty of Dentistry, Department of Periodontology, Samsun, Turkey.
[Ti] Título:Gingival crevicular fluid oxidative stress level in patients with periodontal disease and hyperlipidemia.
[So] Source:Braz Oral Res;31:e110, 2017 Dec 18.
[Is] ISSN:1807-3107
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:This study aimed to assess the impact of hyperlipidemia on healthy and diseased periodontal tissue by evaluating oxidative stress biomarkers in gingival crevicular fluid (GCF). Clinical periodontal parameters and blood serum lipid, GCF malondialdehyde (MDA), protein carbonyl (PC), and total antioxidant capacity (TAOC) levels were evaluated in six age and sex-matched groups (n = 15 each) of normolipidemic and hyperlipidemic individuals as follows: normolipidemic + periodontally healthy (H), normolipidemic + gingivitis (G), normolipidemic + chronic periodontitis (CP), hyperlipidemic + periodontally healthy (HH), hyperlipidemic + gingivitis (HG), and hyperlipidemic + CP (HCP). GCF MDA, and PC levels varied among groups, with patients with periodontitis having the highest MDA and PC levels [CP > G > H (p < 0.01) and HCP > HG > HH (p < 0.01)] and the lowest TAOC levels [CP < G < H (p < 0.01) and HCP < HG < HH (p < 0.01)]. Furthermore, paired comparisons showed MDA and PC levels to be higher and TAOC levels to be lower in HCP compared with NCP (p < 0.01). In patients with hyperlipidemia, GCF, MDA, and PC levels positively correlated with clinical assessments and serum triglycerides (TG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL) levels and negatively correlated with serum high-density lipoprotein cholesterol (HDL) levels, whereas GCF TAOC levels negatively correlated with clinical assessments and serum TG, TC, and LDL levels, but positively correlated with serum HDL levels (p < 0.01). In normolipidemic patients, GCF, MDA, and PC levels positively correlated with clinical assessments and serum TG levels and negatively correlated with serum HDL levels, whereas GCF TAOC levels negatively correlated with clinical assessments and serum TG levels and positively correlated with serum HDL levels (p < 0.01). In conclusion, abnormal serum lipid subfractions could be considered a risk factor for enhancing oxidative stress in GCF in the presence of periodontal disease.
[Mh] Termos MeSH primário: Periodontite Crônica/sangue
Líquido do Sulco Gengival/metabolismo
Gengivite/sangue
Hiperlipidemias/sangue
Estresse Oxidativo/fisiologia
[Mh] Termos MeSH secundário: Adulto
Análise de Variância
Estudos de Casos e Controles
Colesterol/sangue
Periodontite Crônica/etiologia
Ensaio de Imunoadsorção Enzimática
Feminino
Gengivite/etiologia
Seres Humanos
Hiperlipidemias/complicações
Masculino
Malondialdeído/sangue
Meia-Idade
Carbonilação Proteica/fisiologia
Valores de Referência
Estatísticas não Paramétricas
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Triglycerides); 4Y8F71G49Q (Malondialdehyde); 97C5T2UQ7J (Cholesterol)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:D; IM
[Da] Data de entrada para processamento:171222
[St] Status:MEDLINE


  3 / 24372 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28468786
[Au] Autor:Chang WT; Chang CL; Ho CH; Hong CS; Wang JJ; Chen ZC
[Ad] Endereço:Department of Cardiology, Chi Mei Medical Center, Tainan, Taiwan.
[Ti] Título:Long-Term Effects of Unprovoked Venous Thromboembolism on Mortality and Major Cardiovascular Events.
[So] Source:J Am Heart Assoc;6(5), 2017 May 03.
[Is] ISSN:2047-9980
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Patients with unprovoked venous thromboembolism (VTE) are at an increased risk of mortality, but whether their cardiovascular risks also increase remains to be determined. We aimed to investigate the factors associated with overall mortality and major adverse cardiovascular events in patients with unprovoked VTE. METHODS AND RESULTS: We identified 2154 patients newly diagnosed with unprovoked VTE from Taiwan's National Health Insurance Database between 2000 and 2013, excluding those with reversible etiologies, underlying cancer, or autoimmune diseases. These patients with VTE were compared with an age-, sex-, and cardiovascular risk-matched cohort of 4308 controls. The risk of mortality and major adverse cardiovascular events in patients with VTE was 2.23 (CI, 1.93-2.57; <0.0001) and 1.86 (CI, 1.65-2.09; <0.0001) times, respectively, higher than that of the conditions in controls. These events mostly occurred during the first year after the diagnosis of unprovoked VTE. Among patients with VTE, advanced age, male sex, and comorbid diabetes mellitus indicated a higher incidence of mortality and major adverse cardiovascular events. Conversely, comorbid hyperlipidemia attenuated these risks. CONCLUSIONS: This nation-wide cohort study revealed that patients with unprovoked VTE, particularly older males with diabetes mellitus, had an elevated risk of both mortality and cardiovascular events. Risk of mortality and major adverse cardiovascular events were highest within the first year after diagnosis and persisted during the 10 years of follow-up.
[Mh] Termos MeSH primário: Tromboembolia Venosa/mortalidade
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Idoso
Comorbidade
Bases de Dados Factuais
Diabetes Mellitus/diagnóstico
Diabetes Mellitus/mortalidade
Feminino
Seres Humanos
Hiperlipidemias/diagnóstico
Hiperlipidemias/mortalidade
Incidência
Estimativa de Kaplan-Meier
Masculino
Meia-Idade
Prognóstico
Modelos de Riscos Proporcionais
Fatores de Proteção
Estudos Retrospectivos
Medição de Risco
Fatores de Risco
Fatores Sexuais
Taiwan/epidemiologia
Fatores de Tempo
Tromboembolia Venosa/diagnóstico
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE


  4 / 24372 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29443736
[Au] Autor:Tang M; Xu JM; Song SS; Mei Q; Zhang LJ
[Ad] Endereço:Department of Gastroenterology, the First Hospital of Anhui Medical University.
[Ti] Título:What may cause fetus loss from acute pancreatitis in pregnancy: Analysis of 54 cases.
[So] Source:Medicine (Baltimore);97(7):e9755, 2018 Feb.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Acute pancreatitis in pregnancy (APIP) poses a serious threat to the mother and her fetus, and might lead to fetal loss including miscarriage and stillbirth in certain patients. We sought to identify possible factors that affect fetal distress and evaluated outcomes of patients with APIP.We retrospectively reviewed clinical records of 54 pregnant women with APIP, who were treated at 2 tertiary clinical centers over a 6-year period. Clinical characteristics including etiology and severity of APIP, fetal monitoring data, and maternofetal outcomes were analyzed.Etiology of APIP included acute biliary pancreatitis (ABP, n = 14), hyperlipidemic pancreatitis (HLP, n = 22), and other etiologies (n = 18). Severity was classified as mild acute pancreatitis (MAP, n = 23), moderately severe acute pancreatitis (MSAP, n = 24), and severe acute pancreatitis (SAP, n = 7). The incidence of preterm delivery, fetal distress, and fetal loss increased with the progression of severity of APIP (P < .05). The severity of HLP was significantly higher than that of ABP and APIP of other etiology (P < .01). HLP was more likely to lead to fetal distress than other APs (P < .01). Only 12 (22.2%) patients had fetal monitoring including non-stress test (NST); 1 case of SAP (14.3%) and 15 cases of MSAP (62.5%) were not transferred to intensive care unit for intensive monitoring.The incidence of fetal distress and fetal loss increased with worsening of APIP severity. HLP tends to result in worse fetal outcomes. The deficiencies of fetal state monitoring, lack of assessment, and management of pregnant women might increase the fetal loss in APIP.
[Mh] Termos MeSH primário: Morte Fetal/etiologia
Pancreatite/complicações
Complicações na Gravidez
[Mh] Termos MeSH secundário: Doença Aguda
Adulto
Progressão da Doença
Feminino
Sofrimento Fetal/epidemiologia
Sofrimento Fetal/etiologia
Seres Humanos
Hiperlipidemias/complicações
Incidência
Pancreatite/epidemiologia
Pancreatite/etiologia
Gravidez
Complicações na Gravidez/epidemiologia
Complicações na Gravidez/etiologia
Nascimento Prematuro/epidemiologia
Nascimento Prematuro/etiologia
Estudos Retrospectivos
Índice de Gravidade de Doença
Adulto Jovem
[Pt] Tipo de publicação:EVALUATION STUDIES; JOURNAL ARTICLE; MULTICENTER STUDY
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009755


  5 / 24372 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29254319
[Au] Autor:Musolino V; Gliozzi M; Carresi C; Maiuolo J; Mollace R; Bosco F; Scarano F; Scicchitano M; Maretta A; Palma E; Iannone M; Morittu VM; Gratteri S; Muscoli C; Fini M; Mollace V
[Ad] Endereço:Institute of Research for Food Safety and Health (IRC-FSH), Department of Health Science, Magna Græcia University of Catanzaro, Catanzaro, Italy.
[Ti] Título:Lipid-lowering effect of bergamot polyphenolic fraction: role of pancreatic cholesterol ester hydrolase.
[So] Source:J Biol Regul Homeost Agents;31(4):1087-1093, 2017 Oct-Dec.
[Is] ISSN:0393-974X
[Cp] País de publicação:Italy
[La] Idioma:eng
[Ab] Resumo:Bergamot polyphenolic fraction (BPF) has been shown to positively modulate several mechanisms involved in metabolic syndrome, suggesting its use in therapy. In particular, it is able to induce a significant amelioration of serum lipid profile in hyperlipemic patients at different levels. The purpose of our study was to investigate the effect of BPF on cholesterol absorption physiologically mediated by pancreatic cholesterol ester hydrolase (pCEH). An in vitro activity assay was performed to study the effect of BPF on pCEH, whereas the rate of cholesterol absorption was evaluated through in vivo studies. In particular, male, Sprague-Dawley rats (200–225 g) were fed either normal chow or chow supplemented with 0.5% cholic acid, 5.5% peanut oil, and varying amounts of cholesterol (0 to 1.5%). BPF (10 mg/Kg) was daily administrated by means of a gastric gavage to animals fed with lipid supplemented diet for 4 weeks and, at the end of the study, plasma lipids and liver cholesteryl esters were measured in all experimental groups. Our results show that BPF was able to inhibit pCEH activity and this effect was confirmed, in vivo, via detection of lymphatic cholesteryl ester in rats fed with a cholesterol-rich diet. This evidence clarifies a further mechanism responsible for the hypolipemic properties of BPF previously observed in humans, confirming its beneficial effect in the therapy of hypercholesterolemia and in the treatment of metabolic syndrome.
[Mh] Termos MeSH primário: Suplementos Nutricionais
Hiperlipidemias/tratamento farmacológico
Hipolipemiantes/farmacologia
Óleos Vegetais/farmacologia
Esterol Esterase/antagonistas & inibidores
[Mh] Termos MeSH secundário: Animais
Colesterol/administração & dosagem
Colesterol/sangue
Ésteres do Colesterol/sangue
Ácido Cólico/administração & dosagem
Ácido Cólico/sangue
Absorção Gastrointestinal/fisiologia
Seres Humanos
Hiperlipidemias/metabolismo
Hiperlipidemias/patologia
Hipolipemiantes/metabolismo
Fígado/efeitos dos fármacos
Fígado/metabolismo
Masculino
Síndrome Metabólica/tratamento farmacológico
Síndrome Metabólica/metabolismo
Síndrome Metabólica/patologia
Óleos Vegetais/metabolismo
Ratos
Ratos Sprague-Dawley
Esterol Esterase/metabolismo
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cholesterol Esters); 0 (Hypolipidemic Agents); 0 (Plant Oils); 0 (Triglycerides); 39W1PKE3JI (bergamot oil); 97C5T2UQ7J (Cholesterol); EC 3.1.1.- (bile salt-stimulated lipase); EC 3.1.1.13 (Sterol Esterase); G1JO7801AE (Cholic Acid)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171220
[St] Status:MEDLINE


  6 / 24372 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29384954
[Au] Autor:Li G; Qi G; Zhang B; Zhou B; Ma B; Jiang D; He Q; Ai C; Dai H; Li Y; Shi J
[Ad] Endereço:Department of Clinical Epidemiology, Institute of Cardiovascular Diseases.
[Ti] Título:The dose-response association between estimated glomerular filtration rate and prognosis of patients with ST-segment elevation myocardial infarction from rural areas of China's Liaoning province.
[So] Source:Medicine (Baltimore);96(52):e9508, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:We aimed to investigate the dose-response associations between chronic kidney disease (CKD), and short and long-term cardiovascular outcomes, to characterize these associations by drawing dose-response curves based on a Chinese rural ST-segment elevation myocardial infarction (STEMI) population.In all, 1067 patients with STEMI were consecutively enrolled from 12 secondary hospitals of China's Liaoning province (from June 2009 to June 2010 and January 2015 to December 2015). The follow-up was regularly performed by telephone. Patients were grouped by estimated glomerular filter rate (eGFR): normal, eGFR ≥90 mL/min/1.73 m; mild CKD, 60 to 90 mL/min/1.73 m; CKD, <60 mL/min/1.73 m. Adjusted logistic or Cox regression models were employed to compare short and long-term cardiovascular outcomes across different eGFR groups. Dose-response curves were plotted using restricted cubic spline functions.About 18.46% of the STEMI patients had CKD. Patients with CKD were more likely to suffer from other comorbidities, but less likely to receive evidence-based therapies. CKD was independently associated with in-hospital mortality and major adverse cardiac events (MACE) as compared with patients with normal renal function (for in-hospital mortality, adjusted odds ratio [OR] 2.39, 95% confidence interval [CI] 1.18-4.85, P = .02; for in-hospital MACE, adjusted OR 2.01, 95% CI 1.09-3.70, P < .01). Likewise, CKD was significantly associated with long-term mortality as well (CKD vs normal, adjusted hazard ratio 2.55, 95% CI 1.17-5.57, P = .02). The dose-response associations between eGFR, and short and long-term cardiovascular outcomes were found to be linear (all with P values for nonlinear associations >.05).CKD is an independent predictor of worse in-hospital and long-term clinical outcomes. The assessment of eGFR is essential to enable risk stratification, tailored therapy, and early and aggressive management.
[Mh] Termos MeSH primário: Taxa de Filtração Glomerular
Insuficiência Renal Crônica/epidemiologia
Infarto do Miocárdio com Supradesnível do Segmento ST/epidemiologia
[Mh] Termos MeSH secundário: Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Biomarcadores
Doenças Cardiovasculares/epidemiologia
China/epidemiologia
Comorbidade
Proteínas de Drosophila
Feminino
Mortalidade Hospitalar
Seres Humanos
Hiperlipidemias/epidemiologia
Modelos Logísticos
Masculino
Proteínas de Membrana
Meia-Idade
Prognóstico
Modelos de Riscos Proporcionais
Insuficiência Renal Crônica/patologia
População Rural
Infarto do Miocárdio com Supradesnível do Segmento ST/mortalidade
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Biomarkers); 0 (Drosophila Proteins); 0 (Membrane Proteins); 0 (expanded protein, Drosophila)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009508


  7 / 24372 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29381966
[Au] Autor:Liu MX; Wen XY; Leung YK; Zheng YJ; Jin MS; Jin QL; Niu JQ
[Ad] Endereço:Department of Hepatology, The First Hospital of Jilin University.
[Ti] Título:Hemolytic anemia in alcoholic liver disease: Zieve syndrome: A case report and literature review.
[So] Source:Medicine (Baltimore);96(47):e8742, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Zieve syndrome, a rarely reported disease resulting from alcohol abuse, consists of a triad of symptoms: hemolytic anemia, cholestatic jaundice, and transient hyperlipidemia. It is largely under-recognized and under-reported, possibly because of unawareness of the condition by physicians. Here, we report a case of Zieve syndrome managed at the Jilin University First Bethune Hospital. PATIENT CONCERNS: A 30-year-old Chinese woman presented with a 4-month history of fatigue, yellowish discoloration of the eyes, and tea-colored urine. She had been a heavy drinker for 2 years prior to onset of the disease with an average daily alcohol intake of 60 g/d and more than 80 g/d for the previous 6 months. DIAGNOSIS: The diagnosis of Zieve syndrome was confirmed based on hemolysis and cholestatic jaundice secondary to alcoholic liver disease and heavy drinking. Bone marrow biopsy and liver biopsy both supported the diagnosis. INTERVENTIONS: We treated her with abstinence from alcohol and supportive therapy. OUTCOMES: The patient was discharged 14 days after admission with an improvement in symptoms, which continued to subside during the 2-month follow-up period. LESSONS: Doctors confronted with hemolysis in a patient with alcoholic liver disease should be aware of the under-reported Zieve syndrome. Recognition of this syndrome could help doctors avoid unnecessary invasive procedures and emphasize the importance of alcohol abstinence as the mainstay of management. Glucocorticoids may not be useful in treating hemolytic anemia in Zieve syndrome.
[Mh] Termos MeSH primário: Anemia Hemolítica/complicações
Hepatopatias Alcoólicas/complicações
[Mh] Termos MeSH secundário: Adulto
Feminino
Seres Humanos
Hiperlipidemias/etiologia
Icterícia/etiologia
Síndrome
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008742


  8 / 24372 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464819
[Au] Autor:Imran M; Arshad MS; Butt MS; Kwon JH; Arshad MU; Sultan MT
[Ad] Endereço:Department of Diet and Nutritional Sciences, Imperial College of Business Studies, Lahore, Pakistan.
[Ti] Título:Mangiferin: a natural miracle bioactive compound against lifestyle related disorders.
[So] Source:Lipids Health Dis;16(1):84, 2017 May 02.
[Is] ISSN:1476-511X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The current review article is an attempt to explain the therapeutic potential of mangiferin, a bioactive compound of the mango, against lifestyle-related disorders. Mangiferin (2-ß-D-glucopyranosyl-1,3,6,7-tetrahydroxy-9H-xanthen-9-one) can be isolated from higher plants as well as the mango fruit and their byproducts (i.e. peel, seed, and kernel). It possesses several health endorsing properties such as antioxidant, antimicrobial, antidiabetic, antiallergic, anticancer, hypocholesterolemic, and immunomodulatory. It suppresses the activation of peroxisome proliferator activated receptor isoforms by changing the transcription process. Mangiferin protects against different human cancers, including lung, colon, breast, and neuronal cancers, through the suppression of tumor necrosis factor α expression, inducible nitric oxide synthase potential, and proliferation and induction of apoptosis. It also protects against neural and breast cancers by suppressing the expression of matrix metalloproteinase (MMP)-9 and MMP-7 and inhibiting enzymatic activity, metastatic potential, and activation of the ß-catenin pathway. It has the capacity to block lipid peroxidation, in order to provide a shielding effect against physiological threats. Additionally, mangiferin enhances the capacity of the monocyte-macrophage system and possesses antibacterial activity against gram-positive and gram-negative bacteria. This review summarizes the literature pertaining to mangiferin and its associated health claims.
[Mh] Termos MeSH primário: Anti-Inflamatórios/uso terapêutico
Antineoplásicos Fitogênicos/uso terapêutico
Antioxidantes/uso terapêutico
Hipoglicemiantes/uso terapêutico
Nootrópicos/uso terapêutico
Xantonas/uso terapêutico
[Mh] Termos MeSH secundário: Anti-Inflamatórios/química
Anti-Inflamatórios/isolamento & purificação
Antineoplásicos Fitogênicos/química
Antineoplásicos Fitogênicos/isolamento & purificação
Antioxidantes/química
Antioxidantes/isolamento & purificação
Doenças Cardiovasculares/tratamento farmacológico
Doenças Cardiovasculares/patologia
Disfunção Cognitiva/tratamento farmacológico
Disfunção Cognitiva/patologia
Diabetes Mellitus Tipo 2/tratamento farmacológico
Diabetes Mellitus Tipo 2/patologia
Seres Humanos
Hiperlipidemias/tratamento farmacológico
Hiperlipidemias/patologia
Hipoglicemiantes/química
Hipoglicemiantes/isolamento & purificação
Mangifera/química
Neoplasias/tratamento farmacológico
Neoplasias/patologia
Neuralgia/tratamento farmacológico
Neuralgia/patologia
Nootrópicos/química
Nootrópicos/isolamento & purificação
Estresse Oxidativo/efeitos dos fármacos
Xantonas/química
Xantonas/isolamento & purificação
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents); 0 (Antineoplastic Agents, Phytogenic); 0 (Antioxidants); 0 (Hypoglycemic Agents); 0 (Nootropic Agents); 0 (Xanthones); 1M84LD0UMD (mangiferin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12944-017-0449-y


  9 / 24372 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464894
[Au] Autor:Zhao MJ; Wang SS; Jiang Y; Wang Y; Shen H; Xu P; Xiang H; Xiao H
[Ad] Endereço:Nanjing Medical University, Affiliated Nanjing Brain Hospital, No. 264 Guangzhou Road, Nanjing, Jiangsu, 210029, People's Republic of China.
[Ti] Título:Hypolipidemic effect of XH601 on hamsters of Hyperlipidemia and its potential mechanism.
[So] Source:Lipids Health Dis;16(1):85, 2017 May 02.
[Is] ISSN:1476-511X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The novel compound XH601 is a synthesized derivative of formononetin. The present study was to investigate the hypolipidemia effect and potential mechanism of XH601. METHODS: Male Golden Syrian hamsters were induced by high-fat diet (HFD) for eight weeks and the hyperlipidemic model was established successfully. After XH601 treatment, serum and hepatic biochemistry parameters of hamsters were detected and the effect of XH601 on adipose tissue was also analyzed. Furthermore, 3 T3-L1 cell differentiation by Oil-Red-O staining was observed and the mRNA and protein expression of peroxisome proliferator-activated receptors (PPARs) were measured by qRT-PCR and Western-blot in mature adipocytes. RESULTS: The in vivo results suggest that XH601 significantly decreased the adipose weight and levels of serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein (LDL-C), apolipoprotein B (Apo-B), apolipoprotein E (Apo-E), while increased serum high-density lipoprotein (HDL-C). The in vitro results implied that XH601 up-regulated the mRNA and protein expression of both PPARα and PPARß/δ in a dose-dependent manner. CONCLUSIONS: The study suggests that XH601 exhibited strong ability to improve the dyslipidemia in hamsters fed with high-fat diet. The potential mechanism of XH601 was associated with the up-regulation of PPARα and PPARß/δ mRNA and protein expression.
[Mh] Termos MeSH primário: Hiperlipidemias/tratamento farmacológico
Hipolipemiantes/farmacologia
Isoflavonas/farmacologia
PPAR alfa/agonistas
PPAR delta/agonistas
PPAR beta/agonistas
[Mh] Termos MeSH secundário: Células 3T3-L1
Tecido Adiposo/efeitos dos fármacos
Tecido Adiposo/metabolismo
Tecido Adiposo/patologia
Animais
Apolipoproteínas B/sangue
Apolipoproteínas E/sangue
Diferenciação Celular
HDL-Colesterol/sangue
LDL-Colesterol/sangue
Cricetinae
Dieta Hiperlipídica/efeitos adversos
Regulação da Expressão Gênica
Hiperlipidemias/etiologia
Hiperlipidemias/metabolismo
Hiperlipidemias/patologia
Masculino
Mesocricetus
Camundongos
PPAR alfa/genética
PPAR alfa/metabolismo
PPAR delta/genética
PPAR delta/metabolismo
PPAR beta/genética
PPAR beta/metabolismo
RNA Mensageiro/agonistas
RNA Mensageiro/genética
RNA Mensageiro/metabolismo
Triglicerídeos/sangue
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Apolipoproteins B); 0 (Apolipoproteins E); 0 (Cholesterol, HDL); 0 (Cholesterol, LDL); 0 (Hypolipidemic Agents); 0 (Isoflavones); 0 (PPAR alpha); 0 (PPAR delta); 0 (PPAR-beta); 0 (RNA, Messenger); 0 (Triglycerides); 295DQC67BJ (formononetin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180219
[Lr] Data última revisão:
180219
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12944-017-0472-z


  10 / 24372 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
[PMID]:29376304
[Au] Autor:Apryatin SA; Mzhelskaya KV; Trusov NV; Balakina AS; Kulakova SN; Soto SK; Makarenko MA; Riger NA; Tutelyan VA
[Ti] Título:[Comparative characteristics of in vivo models of hyperlipidemia in Wistar rats and C57Bl/6 mice].
[So] Source:Vopr Pitan;85(6):14-23, 2016.
[Is] ISSN:0042-8833
[Cp] País de publicação:Russia (Federation)
[La] Idioma:rus
[Ab] Resumo:In vivo simulation of lipid disorders (hyperlipidemia, obesity, metabolic syndrome, atherosclerosis) is of considerable interest to search for genomic, transcriptomic and metabolomic markers that allow for differential diagnosis, prognosis and selection of personalized diet therapy in patients with such pathology. The aim of the study was the development and characterization of basic biochemical parameters of in vivo models of alimentary hyperlipidemia in outbred rats and inbred mice. The experiment was con­ducted on 48 growing female Wistar rats, and 48 growing female mice of line C57Black/6, which were divided into 12 groups of 8 animals per group. Within 63 days the rats and mice of first (control) group received a balanced semi synthetic diet (BD), the animals of the second groups - high-fat diet (HFD) with 30% of the total fat by weight of dry feed, third groups - BD and fructose solution (Fr) instead of water, the fourth groups -HFD + Fr, fifth groups - BD supplemented with 0.5% cholesterol (Cho) by weight of dry feed, sixth groups - BD with Cho and Fr. The amount and composition of diets consumed were corrected during the experiment for their closest approach in calories. After removal of animals from the experiment there were determined the mass of internal organs, HDL, LDL, total cholesterol, triglycerides, glucose in blood plasma, total lipids and their fatty acid composition in liver, ghrelin, GIP, GLP-1, glucagon, leptin, PAI-1, resistin levels in blood plasma. It was found that in both species the liver is the most sensitive to nutritional imbalance, nutrient exerting the greatest impact on this was Fr. In rats, as compared to mice, there was significantly more pronounced shifts in lipoprotein spectrum in response to nutritional imbalances, especially to the consumption of additional Cho, which was manifested in an increase of LDL, decrease of HDL and magnification of atherogenic index. In the liver of rats fed diets with Cho, marked steatosis developed manifested in a disproportionate increase in the lipid content and accompanied by changes in their fatty acid composition, especially in the ratio ω6 to ω3 PUFAs. Changing of hormones - regula­tors of carbohydrate metabolism (GLP, glucagon) and ghrelin was significantly greater in mice than in rats as a result of consumption of additional Fr. Effect had the opposite direction in two species of Cho and Fr combining on leptin levels. The significance is dis­cussed of the revealed interspecies differences in the light of the characteristics of lipid and glucose metabolism in these two lines of animals that are the most common models of alimentary-dependent diseases.
[Mh] Termos MeSH primário: Carboidratos da Dieta/efeitos adversos
Gorduras na Dieta/efeitos adversos
Modelos Animais de Doenças
Frutose/efeitos adversos
Hiperlipidemias
[Mh] Termos MeSH secundário: Animais
Carboidratos da Dieta/farmacologia
Gorduras na Dieta/farmacologia
Feminino
Frutose/farmacologia
Hiperlipidemias/sangue
Hiperlipidemias/induzido quimicamente
Hiperlipidemias/patologia
Camundongos
Ratos
Ratos Wistar
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Dietary Carbohydrates); 0 (Dietary Fats); 30237-26-4 (Fructose)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180216
[Lr] Data última revisão:
180216
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180130
[St] Status:MEDLINE



página 1 de 2438 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde